



Original Article



An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir

Yi-Qi Liu¹, Chi Zhang¹, Jia-Wen Li¹, Li-Hua Cao², Zhan-Qing Zhang³, Wei-Feng Zhao⁴, Qing-Hua Shang⁵, Da-Zhi Zhang⁶, An-Lin Ma⁷, Qing Xie⁸, Hong-Lian Gui⁸, Guo Zhang⁹, Ying-Xia Liu¹⁰, Jia Shang¹¹, Shi-Bin Xie¹², Jun Li¹³, Xu-Qing Zhang¹⁴, Zhi-Qiang Zou¹⁵, Yu-Ping Chen¹⁶, Zong Zhang¹⁷, Ming-Xiang Zhang¹⁸, Jun Cheng¹⁹, Fu-Chun Zhang²⁰, Li-Hua Huang²¹, Jia-Bin Li²², Qing-Hua Meng²³, Hai-Bin Yu²³, Yu-Qiang Mi²⁴, Yan-Zhong Peng²⁵, Zhi-Jin Wang²⁶, Li-Ming Chen²⁷, Fan-Ping Meng²⁷, Wan-Hua Ren²⁸, Lang Bai²⁹, Yi-Lan Zeng³⁰, Rong Fan³¹, Xian-Zhi Lou³², Wei-Feng Liang³³, Hui Liu³⁴, Hui Zhuang³⁵, Hong Zhao^{1,36*} 
and Gui-Qiang Wang^{1,36*} 

¹Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China; ²Department of Hepatology, The Third Hospital of Qinhuangdao, Qinhuangdao, Hebei, China; ³Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; ⁴Department of Infectious Disease, Xinxiang Medical University Affiliated Third Hospital, Xinxiang, Henan, China; ⁵No. 88 Hospital of Chinese People's Liberation Army (PLA), Jinan, Shandong, China; ⁶Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; ⁷Department of Infectious Disease, China-Japan Friendship Hospital, Beijing, China; ⁸Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China; ⁹Department of Gastroenterology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China; ¹⁰Department of Infectious Diseases, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China; ¹¹Department of Infectious Diseases, The People's Hospital of Henan Province, Zhengzhou, Henan, China; ¹²Department of Infectious Disease, The Third Affiliated Hospital of Sun-Yat Sen University, Guangzhou, Guangdong, China; ¹³Department of Infectious Diseases, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; ¹⁴Department of Infectious Diseases, The Southwest Hospital of Army Medical University, Chongqing, China; ¹⁵Yantai Infectious Diseases Hospital, Yantai, Shandong, China; ¹⁶Department of Hepatology, Baoding Infectious Diseases Hospital, Baoding, Hebei, China; ¹⁷Department of Integrated Traditional Chinese Medicine (TCM) and Western Medicine, Jinan Infectious Diseases Hospital, Shandong University, Jinan, Shandong, China; ¹⁸Department of Integrated TCM and Western Medicine in Hepatology, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China; ¹⁹Beijing Ditan Hospital, Capital Medical University, Beijing, China; ²⁰Department of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China; ²¹Department of Hepatology, Wuxi No. 5 People's Hospital, Wuxi, Jiangsu, China; ²²The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; ²³Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China; ²⁴Tianjin Second People's Hospital, Tianjin, China; ²⁵Department of Infectious Diseases, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China; ²⁶No. 305 Hospital of PLA, Beijing, China; ²⁷Department of Hepatology, The Fifth Medical Center of the PLA General Hospital, Beijing, China; ²⁸Department of Infectious Diseases, Shandong Provincial Hospital, Jinan, Shandong, China; ²⁹Department of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China; ³⁰Department of Hepatology, The Public Hospital Center of Chengdu, Chengdu, Sichuan, China; ³¹Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China; ³²Department of Infectious Diseases, The Affiliated Central Hospital of Shenyang Medical College, Shenyang, Liaoning, China; ³³Department of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China; ³⁴Department of Pathology, Beijing Youan Hospital, Capital Medical University, Beijing, China; ³⁵Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China; ³⁶Department of Infectious Diseases, Peking University International Hospital, Beijing, China

Received: 19 February 2022 | Revised: 12 May 2022 | Accepted: 16 May 2022 | Published: 6 June 2022

Keywords: Chronic hepatitis B; Liver fibrosis; Regression; Randomized controlled trial.

Abbreviations: ALHX, An-Luo-Hua-Xian; APRI, aspartate aminotransferase to platelet ratio index; CHB, Chronic Hepatitis B; ETV, Entecavir; F, liver histologic fibrosis score; FIB-4, fibrosis-4 score; HAI, liver histologic activity scores of inflammation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LSM, liver stiffness measurement; OR, odds ratio; TCM, traditional Chinese medicine.

***Correspondence to:** Gui-Qiang Wang and Hong Zhao, Department of Infectious Diseases and Center for Liver Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. ORCID: <https://orcid.org/0000-0002-0317-7536> (GQW), <https://orcid.org/0000-0002-8069-9901> (HZ). Tel: +86-13911405123 (GQW), +86-13810765943 (HZ), Fax: +86-10-66551680, E-mail: john131212@126.com and john131212@sina.com (GQW), zhaohong_pufh@bjmu.edu.cn (HZ)

Abstract

Background and Aims: Chronic hepatitis B (CHB) can cause liver fibrosis and lead to cirrhosis and cancer. As the effectiveness of antiviral therapy to reverse liver fibrosis is limited, We aimed to evaluate the effect of An-Luo-Hua-Xian pill (ALHX) on fibrosis regression in CHB patients treated with entecavir (ETV). **Methods:** Treatment-naïve patients with CHB were randomly treated with ETV alone or combined with ALHX (ETV+ALHX) between October 1, 2013 and December 31, 2020. Demographic, laboratory, and liver histology data before and after 78 weeks of treatment were collected. The Ishak fibrosis score (F) was used and fibrosis regression required a decrease in F of ≥ 1 after treatment. **Results:** A total of 780 patients were enrolled, and 394 with a second liver biopsy after treatment were included in the per-protocol population, 132 in ETV group and 262 in ETV+ALHX group. After 78 weeks of treatment, the fibrosis regression rate in the ETV+ALHX group was significantly higher than that of the ETV group at baseline $F \geq 3$ patients: 124/211 (58.8%) vs. 45/98 (45.9%), $p=0.035$. The percentage of patients with a decreased liver stiffness measurement (LSM) was higher in the ETV+ALHX group: 156/211 (73.9%) vs. 62/98 (63.3%), $p=0.056$. Logistic regression analysis showed that ETV combined with ALHX was associated with fibrosis regression [odds ratio (OR)=1.94, $p=0.018$], and a family history of hepatocellular carcinoma was on the contrary. (OR=0.41, $p=0.031$). **Conclusions:** ETV combined with ALHX increased liver fibrosis regression in CHB patients.

Citation of this article: Liu YQ, Zhang C, Li JW, Cao LH, Zhang ZQ, Zhao WF, *et al*. An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir. J Clin Transl Hepatol 2022. doi: 10.14218/JCTH.2022.00091.

Introduction

Chronic hepatitis B virus (HBV) infection is a serious public health problem, especially in China.¹ Liver fibrosis caused by chronic hepatitis B (CHB) is the key in occurrence of liver cirrhosis and liver cancer. If CHB patients are not diagnosed and treated in time, most of them will die of decompensated liver cirrhosis or HCC. CHB accounts for 30% of all liver cirrhosis deaths and 40% of HCC deaths.² Many studies have shown that antiviral therapy is effective in improving HBV-related liver fibrosis. The improvement rate of hepatic fibrosis in newly treated CHB patients with entecavir (ETV) for 48 weeks is reported as 32–39%.³ Although liver fibrosis was improved in more than half of patients, there are still no clearly recommended antifibrosis drugs.

In recent decades, through continuous research and experiments, traditional Chinese medicine (TCM) has made remarkable progress in the treatment of chronic liver disease, and many drugs for the treatment of liver fibrosis have been approved by the State Drug Administration of China. Studies have shown that TCM alone or combined with anti-HBV drugs was effective in delaying or reversing liver fibrosis/cirrhosis.^{4,5} An-Luo-Hua-Xian pill (ALHX, National Medical Products Administration Approval No. Z20010098) is a Chinese patent drug containing more than ten kinds of TCMs.⁶ The components are *Rehmannia glutinosa* (Di Huang), *Radices pseudo-ginseng* (San Qi), *Leech* (Shui Zhi), *Bombyx batryticatus* (Jiang Can), *Pheretima* (Di Long), *Atractylodes macrocephalae* (Bai Zhu), *Curcumae radix* (Yu Jin), *Bovis calculus* (Niu Huang), *Arcae concha* (Wa Neng Zi), *Moutan cortex* (Mu Dab Pi), *Radices rhei* (Da Huang), *raw Hordei*

fructus erminates (Sheng Mai Ya), *Galli gigerii endothelium corneum* (Ji Nei Jin) and powdered buffalo horn extract (Concentrated powder of Shui Niu Jiao). "Luo" in Chinese means collateral branches of the pathway system that runs the "Qi" and blood of the whole body, "Xian" means fibrosis, "An" means to calm or pacify and "Hua" means to soften or alleviate. ALHX regulates immunity, improve liver microcirculation, promote hepatocyte injury and repair collagen synthesis and promote collagen degradation.⁷ Our previous study found that in CHB patients with significant fibrosis (fibrosis grade ≥ 3), ETV combined with ALHX significantly improved the regression rate of liver fibrosis/cirrhosis compared with ETV alone.⁸ Larger studies are needed to confirm the curative effectiveness, develop standard treatment regimens for reversing liver fibrosis, and promote its clinical use. Based on previous investigations, we carried out a prospective randomized controlled trial to further clarify the antifibrosis effectiveness of ALHX in CHB patients.

Methods

Study design and patients

This multicenter, open-label prospective randomized controlled trial was conducted in 33 hospitals in mainland China between October 1, 2013 and December 31, 2020. Eligible patients consented to participate in the study. The inclusion criteria were (1) 18–70 years of age, (2) hepatitis B surface antigen (HBsAg+)-positive for ≥ 6 months or with pathologically confirmed chronic HBV infection, (3) HBV DNA positive, and (4) having regular follow-up. Exclusion criteria were (1) other types of viral hepatitis, i.e. hepatitis C virus, hepatitis D virus, or human immunodeficiency virus co-infection; and other chronic liver diseases (e.g., autoimmune hepatitis, drug-induced liver damage, genetic, nonalcoholic fatty liver); (2) decompensated manifestations of liver cirrhosis, including ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, spontaneous bacterial peritonitis and other complications of liver cirrhosis or primary liver cancer; (3) unstable diabetes, hypertension, thyroid diseases and autoimmune diseases; (4) patients with serious diseases of heart, lung, kidney, brain, blood and other important organs with dysfunction; (5) patients with severe neurological and mental diseases (e.g., epilepsy, depression, mania, schizophrenia, etc.); (6) pregnancy or lactation.

Patients were randomly assigned 2:1 to receive either ETV+ALHX or ETV group by simple randomization with no stratification. Randomized treatment was open-label. The study coordinator assigned patients serial numbers that were linked to a computer-generated randomization list assigning the treatment regimens. ALHX 6 g/bid was administered orally. All patients signed informed consent forms before enrollment. Study procedures followed the ethical principles of the Helsinki Declaration and were approved by The Ethical Committees of Peking University First Hospital. The complete protocol for the clinical trial was registered at ClinicalTrials.gov (NCT01962155 and NCT03568578).

Liver biopsy and scoring system

Liver histological specimens (paraffin embedded) were collected by percutaneous ultrasound-guided liver biopsy and transported to a central laboratory for interpretation. Specimens were considered adequate for scoring if they were more than 2.0-cm long and contained at least 11 portal tracts. They were assessed by two professional liver pa-

thologists from Capital Medical University affiliated Beijing You-An Hospital under double-blind conditions. If the results of the two pathologists were different, or the interpretation results differed with the local pathology, the results were determined by joint discussion with a third pathologist.

The evaluation of liver fibrosis (F) was divided into six stages (0–6), and necroinflammatory scores were assigned using a modified histological activity index (HAI) as described by Ishak *et al*.⁹ F \geq 3 was considered significant fibrosis. Fibrosis regression after treatment required a decrease in F \geq 1, and progression required an increase in F of at least one stage. Histological improvement required a decrease of the HAI of at least two grades and no fibrosis progression.

Endpoints

The primary endpoints were liver fibrosis regression and reduction of liver stiffness measurement (LSM). LSM was divided into four levels,^{10,11} <7.4 , $7.4 \leq \text{LSM} <9.4$, $9.4 \leq \text{LSM} <12.4$, and ≥ 12.4 . LSM reduction required a decrease of at least one level after treatment. Secondary endpoints included histological improvement and noninvasive fibrosis index reduction, biochemical, virological, and serological responses. Noninvasive fibrosis indexes were fibrosis-4-score (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) were calculated from biochemical data. FIB-4 was divided into three levels,^{12,13} FIB-4 <1.45 , FIB-4 ≥ 1.45 and an intermediate level, FIB-4 reduction required a decrease on one level, the same as LSM. APRI was divided into three levels,¹⁴ <1.00 , ≥ 1.00 and an intermediate level, APRI reduction also required a decrease of at least one level. Qualitative assay of HBsAg was performed with available enzyme-linked immunosorbent assays (Roche Diagnostics Co., Penzberg, Germany), HBV DNA was assayed with Roche COBAS AmpliPrep/COBAS TaqMan assay (Roche Co., Penzberg, Germany) with a lower limit of detection of 20 IU/mL, and assay of serum hepatitis B core antibody (anti-HBc) was with a chemiluminescent particle immunoassay (Wantai Co., Xiamen, China). All assays were performed by a central laboratory at Peking University First Hospital. Biochemical data and transient elastography results (i.e. LSM) were collected at local study centers.

Statistical analysis

Quantitative variables were reported as medians and lower and upper quartiles or means \pm standard deviations (SDs). Categorical variables were reported as numbers and percentage. The *t*-test or Kruskal-Wallis test were used to compare continuous variables. Chi-square or Fisher's exact test were used to compare categorical variables. Logistic regression was used to analyze factors associated with fibrosis regression. *P*-values <0.05 was considered statistically significant. The statistical analysis was performed with SPSS 24.0 (IBM Corp., Armonk, NY, USA).

Results

Study population

A total of 1,328 HBsAg (+) patients were screened between October 1, 2013 and December 31, 2020 and 780 CHB patients with liver biopsy were randomized in the intention-to-treat (ITT) population, 258 patients in the ETV group and 522 patients in the ETV+ALHX group. A total of 394 patients

with a second liver biopsy after treatment were finally enrolled in the per-protocol (PP) population, 132 in the ETV group and 262 in the ETV+ALHX group. The enrollment protocol is shown in Figure 1. In the PP population, both groups included mainly male patients with an average age of about 40 years, and a body mass index (BMI) of 23–24 kg/m². There were no significant difference between two groups in the baseline demographic and clinical characteristics except for HAI grade. The baseline characteristics of the PP population are shown in Table 1, the characteristics of the PP population with significant fibrosis are shown in Supplementary Table 1 and those of ITT population are shown in Supplementary Table 2.

Endpoints

Primary endpoints: Patients with baseline F \geq 3 in the ETV+ALHX group had a significantly higher rate of fibrosis regression (124/211, 58.8%) than those in the ETV group (45/98, 45.9%) after 78 weeks of treatment ($p=0.035$, Table 2). Patients in ETV+ALHX group also has a higher fibrosis regression rate than those in the ETV group [130/262 (49.6%) and 53/132 (40.2%); Table 2] but the difference was not significant ($p=0.075$). The distribution of F stage at baseline and after 78 weeks treatment for both groups are shown in Figure 2. Change in fibrosis after treatment compared with baseline is shown in Supplementary Table 3. We also measured fibrosis regression in LSM, APRI and FIB-4. Patients with a baseline F \geq 3, LSM reduction rate in ETV+ALHX group (73.9%) was also higher than in the ETV group (63.3%), $p=0.056$. FIB-4 and APRI in the two groups before and after treatment are also shown in Table 2. The distribution of LSM, APRI and FIB-4 at baseline and after treatment and changes in the two groups before and after treatment are shown in Figure 3.

Secondary endpoints: The rates (i.e. percentages) of patients with normalized ALT and those with a HBV DNA decrease ≥ 2 -times the log value, HBV DNA ≤ 20 IU/mL, HBeAg clearance, and HBeAg seroconversion in the ETV+ALHX group and ETV group were not significantly different (Table 2). The percentage of patients with baseline F \geq 3 and an HAI decrease ≥ 2 grades was significantly higher in the ETV+ALHX group than in the ETV group (67.3% vs. 53.1%, $p=0.016$). Histological improvement rate in ETV+ALHX group also has a higher trend in both all patients (55.3% vs. 46.2%) and F \geq 3 patients (58.3% vs. 49.0%, Table 2).

Factors related to fibrosis regression

We divided significant fibrosis patients (baseline F \geq 3) into regression and no regression groups (the stage of baseline F was equal to or increased after treatment) according to the treatment outcome. ETV+ALHX group had a higher rate of fibrosis regression (73.4% vs. 62.1%, $p=0.035$) and family history of HCC made patients more difficult to achieve fibrosis regression (7.7% vs. 17.1%, $p=0.026$). Variables with $p < 0.2$ in univariate analysis were selected for logistic regression and multivariate analysis, we found that combined with ALHX (OR=1.94, 95% CI: 1.12–3.37, $p=0.018$), no family history of HCC, high platelet count and low international normalized ratio made a significant difference related to fibrosis regression. Detailed results were showed in Table 3.

Safety

Two patients in the ETV+ALHX group had mild diarrhea, but after evaluation by the attending physician and symptomat-




Fig. 1. Flowchart of enrollment.

ic treatment, the symptoms were relieved soon. The dosage was not reduced. No noticeable severe adverse effects related to the drug use were observed during the study in groups. Two patients in the ETV+ALHX group withdrew from the study because of liver cancer that was judged not to be associated with treatment. One is 57-year-old with a family history of HCC and the other is a 33-year-old with a known HBsAg positive duration of 29 years.

Discussion

In this study, we found that ALHX was effective for the regression of liver fibrosis in CHB patients using ETV, espe-

cially in those with baseline $F \geq 3$ ($p=0.035$). Using transient elastography to estimate liver fibrosis, the LSM degradation rate was higher in the ETV+ALHX group than the ETV group in baseline $F \geq 3$ patients (73.9% vs. 63.3%, $p=0.056$), non-invasive fibrosis indexes such as FIB-4 and APRI, the degradation rates in ETV+ALHX group were also higher, but more patients may be needed to reach statistical significance. We calculated patients with no or mild liver fibrosis ($F < 3$) and the effect of adding ALHX may be more inclined to maintain liver in mild fibrosis: Fibrosis was stable in 9 (9/34, 26.5%) patients in the ETV group and in 29 (29/51, 56.9%) in the ETV+ALHX group, $p=0.006$. Fibrosis progressed in 17 (17/34, 50.0%) ETV patients and 16 (16/51, 31.4%) in ETV+ALHX patients, $p=0.084$. In significant fibrosis pa-

Table 1. Baseline demographic and clinical characteristics

	ETV	ETV+ALHX	p-value
N	132	262	
Age, year	40.68±11.58	40.92±10.07	0.831
<40, n (%)	63 (47.7)	125 (47.7)	
≥40, n (%)	69 (52.3)	137 (52.3)	
Male sex, n (%)	104 (78.8)	190 (72.5)	0.177
BMI (kg/m ²)	23.52±3.03	24.00±3.27	0.163
Family history of HBV infection, n (%)	57 (43.2)	131 (50.4)	0.177
Family history of HCC, n (%)	17 (12.9)	31 (11.9)	0.775
History of drinking, n (%)	4 (3.0)	5 (1.9)	0.491
History of smoking, n (%)	26 (19.7)	65 (24.9)	0.248
HBsAg positive duration, year	10 (3, 20)	11 (4, 20)	0.270
WBC (×10 ⁹ /L)	5.49±1.58, 5.36	5.33±1.45, 5.11	0.295
LY%	34.99±8.62, 35.50	35.13±8.88, 35.10	0.879
HGB (g/L)	146.77±16.95, 150	144.74±16.8, 147	0.259
PLT (×10 ⁹ /L)	161.08±50.10, 158.50	156.87±52.67, 153.00	0.447
ALT (U/L)	57.30 (37.71, 106.00)	56.00 (34.00, 105.71)	0.173
AST (U/L)	39.38 (28.00, 67.95)	41.00 (29.00, 67.95)	0.053
ALP (U/L)	86.00 (73.80, 112.00)	82.46 (67.00, 108.64)	0.516
GGT (U/L)	37.65 (25.10, 73.80)	41.33 (25.00, 78.15)	0.872
ALB (g/L)	43.37±4.57, 43.05	42.60±4.84, 43.00	0.650
TBiL (μmol/L)	15.40 (10.80, 19.60)	14.60 (11.70, 20.00)	0.251
DBiL (μmol/L)	4.95 (3.35, 6.90)	4.60 (3.40, 7.50)	0.123
Cr (μmol/L)	66.77±13.07, 66.00	67.84±14.58, 66.90	0.960
TCHO (mmol/L)	4.26±0.84, 4.09	4.40±0.86, 4.42	0.122
TG (mmol/L)	1.10±0.55, 0.95	1.15±0.58, 1.02	0.411
AFP (ng/mL)	4.59 (2.82, 7.59)	4.60 (2.75, 15.32)	0.815
INR	1.09±0.12, 1.09	1.09±0.13, 1.08	0.975
HBV DNA (log ₁₀ IU/mL)	5.78±1.78, 6.01	5.63±1.92, 5.75	0.470
HBsAg (log ₁₀ IU/mL)	3.32±0.70, 3.41	3.36±0.71, 3.39	0.589
HBeAg (+), n (%)	84 (63.6)	138 (52.7)	0.053
qAnti-HBc (log ₁₀ IU/mL)	3.73±0.76, 3.75	3.85±0.77, 3.91	0.149
LSM (kPa)	10.45 (7.80, 16.30)	11.90 (8.30, 18.00)	0.117
HAI			0.025
≤ 4, n (%)	41 (31.1)	68 (26.0)	
5–6, n (%)	50 (37.9)	72 (27.5)	
7–9, n (%)	30 (22.7)	83 (31.7)	
≥10, n (%)	11 (8.3)	39 (14.9)	
F			0.306
<3, n (%)	34 (25.8)	51 (19.5)	
3–4, n (%)	68 (51.5)	153 (58.4)	
5–6, n (%)	30 (22.7)	58 (22.1)	

All values shown are based on available data, and are means±SDs or medians (range). AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; Cr, creatinine; DBiL, direct bilirubin; F, liver fibrosis score; GGT, glutamyl transferase; HAI, liver histologic activity scores of inflammatory; HBV, hepatitis B virus; HCC, hepatocellular carcinoma HGB, hemoglobin; INR, international normalized ratio; LSM, liver stiffness measurement; LY%, percentage of lymphocyte; PLT, platelet; qAnti-HBc, quantitative anti-hepatitis B core antigen; TBiL, total bilirubin; TCHO, total cholesterol; TG, triglyceride; WBC, white blood cell.

Table 2. Treatment efficacy of the ETV group and ETV+ALHX group

	ETV	ETV+ALHX	p-value
All patients, <i>n</i>	132	262	
ALT normalization, <i>n</i> (%)	83/90 (92.2)	159/178 (88.8)	0.449
HBV DNA decreased $\geq 2 \times \lg$, <i>n</i> (%)	118 (89.4)	238 (90.8)	0.646
HBV DNA ≤ 20 IU/mL, <i>n</i> (%)	100 (75.8)	203 (77.5)	0.702
HBeAg clearance, <i>n</i> (%)	26 (19.7)	44 (16.9)	0.498
HBeAg seroconversion, <i>n</i> (%)	9 (6.8)	11 (13.3)	0.271
Histological improvement ¹ , <i>n</i> (%)	61 (46.2)	145 (55.3)	0.087
HAI decreased ≥ 2 , <i>n</i> (%)	74 (56.1)	173 (66.0)	0.053
Fibrosis changes ²			
Regression, <i>n</i> (%)	53 (40.2)	130 (49.6)	0.075
Progression, <i>n</i> (%)	30 (25.1)	45 (17.2)	0.185
LSM degradation ³ , <i>n</i> (%)	80 (60.6)	179 (68.7)	0.109
FIB-4 degradation ⁴ , <i>n</i> (%)	47 (35.6)	96 (36.6)	0.840
APRI degradation ⁵ , <i>n</i> (%)	47 (35.6)	107 (40.8)	0.315
F ≥ 3 patients, <i>n</i>	98	211	
ALT normalization, <i>n</i> (%)	65/70 (92.9)	126/144 (87.5)	0.235
HBV DNA decreased $\geq 2 \log_{10}$, <i>n</i> (%)	90 (91.8)	191 (90.5)	0.708
HBV DNA ≤ 20 IU/mL	75 (76.5)	166 (78.7)	0.672
HBeAg clearance, <i>n</i> (%)	14 (14.3)	33 (15.8)	0.733
HBeAg seroconversion, <i>n</i> (%)	1 (1.0)	8 (3.8)	0.174
Histological improvement ¹ , <i>n</i> (%)	48 (49.0)	123 (58.3)	0.125
HAI decreased ≥ 2 , <i>n</i> (%)	52 (53.1)	142 (67.3)	0.016
Fibrosis changes ²			
Regression, <i>n</i> (%)	45 (45.9)	124 (58.8)	0.035
Progression, <i>n</i> (%)	13 (13.3)	29 (13.7)	0.909
LSM degradation ³ , <i>n</i> (%)	62 (63.3)	156 (73.9)	0.056
FIB-4 degradation ⁴ , <i>n</i> (%)	33 (33.7)	77 (36.5)	0.630
APRI degradation ⁵ , <i>n</i> (%)	37 (37.8)	88 (41.7)	0.510

¹HAI decreased ≥ 2 grades and fibrosis stage was not increased after treatment. ²Regression required a decrease of ≥ 1 in fibrosis stage after treatment; Progression required an increase of ≥ 1 in fibrosis stage after treatment. ³LSM was divided into four grades: <7.4 , $7.4 \leq \text{LSM} < 9.4$, $9.4 \leq \text{LSM} < 12.4$, and ≥ 12.4 , grade decreased ≥ 1 after treatment. ⁴FIB-4 was divided into three grades: <1.45 , $1.45 \leq \text{FIB-4} < 3.25$, and ≥ 3.25 , grade decreased ≥ 1 after treatment. ⁵APRI was divided into three grades: <1.00 , $1.00 \leq \text{APRI} < 2.00$, and ≥ 2.00 , grade decreased ≥ 1 after treatment. ALT, alanine aminotransferase; HAI, liver histologic activity scores of inflammation; HBV, hepatitis B virus; ALHX, An-Luo-Hua-Xian; APRI, aspartate aminotransferase to platelet ratio index; ETV, Entecavir; F, liver histologic fibrosis score; FIB-4, fibrosis-4-score.

tients (baseline F=3–4), the decrease rate of F to <3 in ETV+ALHX group was higher than that in ETV group (30.1% vs. 19.1%, $p=0.090$), and in cirrhosis patients (baseline F=5–6), the rates were 17.2% and 3.3% ($p=0.089$). The rates of cirrhosis regression to <5 after treatment in the two groups were 75.9% and 63.3% ($p=0.217$). This tendency is consistent with other studies such as Kong *et al.*¹⁵ who found that ETV combined with ALHX increased the survival rate of decompensated hepatitis B patients after 5-year (67.85% vs. 26.19%, $p<0.01$). Animal model studies have shown that ALHX has a positive role in anti-fibrosis. Lu *et al.*¹⁶ showed it reversed CCl₄-induced liver fibrosis in rats, and its mechanism may be through affecting transforming growth factor beta 1, which inhibits the activation of hepatic stellate cells (HSC) and has an anti-fibrosis role. Wang *et al.*¹⁷ found that the antifibrosis effect of ALHX may

occur through the upregulation of peroxisome proliferator-activated receptor-gamma (PPAR γ) expression and down-regulation of the nuclear factor-kappa B/inhibitor α of NF- κ B (NF- κ B/I κ B α) signaling pathway. PPAR γ has a role in adipocyte differentiation and lipid metabolism. Its antifibrotic effect may act by regulating the adipogenic phenotype of HSC.¹⁸ NF- κ B acts as a key regulator of inflammation, NF- κ B transcriptional activity has been shown to increase and be maintained at a high level when HSCs are activated.¹⁸ However, more large clinical studies are needed to clarify the antifibrosis effect and its mechanisms.

Other Chinese patent drugs such as Biejia-Ruangan (BR) and Fu-Zheng-Hua-Yu (FZHY) have an antifibrosis effect in clinical therapy. Rong *et al.*¹⁹ in a study of 1,000 CHB patients (705 with a second biopsy), reported that the rate of fibrosis regression after 72 weeks of treat-




Fig. 2. Distribution of fibrosis scores in both study groups before and after 78 weeks of treatment.

ment was significantly higher in the ETV+BR group than in the ETV group (40% vs. 31.8%, $p=0.0069$). Huang *et al.*²⁰ found that BR inhibited hepatic collagen deposition and improved liver injury in rats with CCl₄-induced hepatic fibrosis, which was associated with downregulation of the transforming growth factor beta- β -Smad pathway. As early as 2005, a multicenter clinical trial confirmed the antifibrosis effectiveness and safety of FZHY in CHB patients.²¹ A single-center clinical study by Gui *et al.*,²² which included 46 CHB patients with a second liver biopsy, reported that ETV+ FZHY had a significantly higher rate of fibrosis regression (82% vs. 54%, $p<0.05$). In mice with fibrosis induced by CCl₄ and dimethylnitrosamine, it was observed that FZHY not only was effective against fibrosis, it also improved CCl₄ and dimethylnitrosamine-induced sinus capillary formation and expression of angiogenesis and angiogenesis-related factors.²³ Hepatic sinusoidal capillarization and angiogenesis in the fibrous septum connecting the portal vein and the central hepatic vein are two key events leading to liver cirrhosis.²⁴ Further controlled studies are needed to compare the efficacy of

these traditional Chinese medicines.

Loomba *et al.*²⁵ found that a family history of HCC multiplied the risk of HCC associated with HBV infection. The cumulative risk was 15.8% with vs. 7.5% without a family history ($p<0.001$). Our study found that a family history of HCC affected the regression of liver fibrosis, so it may lead to the progression of fibrosis and eventually develop into liver cirrhosis and HCC. Therefore, in guidelines for the diagnosis and treatment of CHB, it is suggested that patients with a family history of HCC should start antiviral treatment.^{3,26} Univariate and multivariate analysis in our study also showed that in patients with significant fibrosis, there was a negative correlation between histological evidence of fibrosis regression and a family history of HCC. As we know, HBV has at least nine different genotypes. Genotypes B and C are the most prevalent in China, and genotype C is associated with earlier progression to HCC.²⁷ Our study provides additional support for the guideline recommendation for starting combined antifibrosis and antiviral treatment of these CHB patients as soon as possible. However, the relationship between a family history of HCC




Fig. 3. Distribution of LSM, APRI and FIB-4 in the study groups before and after treatment (A, B, C) and changes in the groups before and after treatment (D, E, F).

and lack of fibrosis regression and the incidence of HCC needs further study to clarify the cause.

This study has several limitations. Firstly, nearly half the patients with a first liver biopsy had a second one after treatment. We tried our best to communicate with patients, but partly because of COVID-19, some patients could not return to hospital for follow-up. Secondly, ALHX is a patent Chinese drug containing more than ten kinds of traditional Chinese medicines. We have not studied the antifibrosis effectiveness of single components. Our study showed that ALHX combined with antiviral therapy reversed liver fibrosis, but its specific antifibrosis components need to be studied. Thirdly, our study did not use a placebo in the ETV group and only observed the results of 78 weeks of treatment. We need longer patient follow-up and are working on it.

Conclusion

In CHB patients using ETV, combined treatment with ALHX increased the rates of liver fibrosis regression after 78 weeks treatment in baseline $F \geq 3$ patients as shown by invasive liver biopsy or noninvasive methods such as LSM, etc. Logistic regression analysis found that ALHX was associated with the regression outcome and that a family history of HCC had the opposite association. In patients with significant fibrosis, we recommend combining antiviral therapy and ALHX as soon as possible.

Acknowledgments

We thank all the patients who participated in this study,

as well as all the researchers in local centers. In addition, we thank Cosunter Pharmaceutical Technology and Sunlon Pharmaceutical Technology for providing free drugs, Ashermmed Pharmaceutical Technology Co. Ltd for its participation in data checking and collation.

Funding

This study was supported by National Science and Technology Major Project (2013ZX10002005 and 2017ZX10203202).

Conflict of interest

The authors have no conflict of interests related to this publication.

Author contributions

Conceptualization (Liu YQ, Zhao H, Wang GQ), methodology (Liu YQ, Zhang C, Li JW), formal analysis and investigation, (Liu YQ, Zhang C, Li JW), writing - original draft preparation (Liu YQ), writing - review and editing (Zhuang H, Hong Zhao, Zhao H, Wang GQ), funding acquisition (Wang GQ), material preparation and data collection (Cao LH, Zhang ZQ, Zhao WF, Shang QH, Zhang DZ, Ma AL, Xie Q, Gui HL, Zhang G, Liu YX, Shang J, Xie SB, Li J, Zhang QX, Zou ZQ, Chen YP, Zhang Z, Zhang MX, Cheng J, Zhang FC, Huang LH, Li JB, Meng QH, Yu HB, Mi YQ, Peng YZ, Wang ZJ, Chen LM, Meng FP, Ren WH, Bai L, Zeng YL, Fan R, Lou XZ, Liang WF, Liu H; Supervision: Zhao H, Wang GQ).

Table 3. Analysis of factors associated with fibrosis regression in F23 patients

	Regression	No regression	Uni	p-value ¹	Multi	p-value ²
N	169	140				
ETV+ALHX group	124 (73.4)	87 (62.1)	4.46	0.035	1.94 (1.12, 3.37)	0.018
Age (years)	41.12±10.51	42.34±10.72	-1.00	0.316		
<40, n (%)	79 (46.7)	58 (41.4)	0.88	0.349		
Male sex, n (%)	121 (71.6)	102 (72.9)	0.06	0.81		
Family history of HBV infection, n (%)	81/167 (48.5)	72 (51.4)	0.26	0.610		
Family history of HCC, n (%)	13/168 (7.7)	24 (17.1)	6.39	0.011	0.41 (0.18, 0.92)	0.031
History of drinking, n (%)	5 (3.0)	4 (2.9)	0.00	0.958		
HBsAg positive duration, year	11 (4, 20)	10 (2, 20)	-0.26	0.794		
BMI (kg/m ²)	23.98±3.43, 23.62	24.22±3.04, 24.22	-0.64	0.524		
WBC (×10 ⁹ /L)	5.47±1.58, 5.30	5.32±1.56, 5.18	0.77	0.443		
LY%	34.93±7.84, 34.6	34.83±9.61, 35.9	0.11	0.918		
HGB (g/L)	143.91±17.38, 147	146.22±16.76, 148	-1.19	0.237		
PLT (×10 ⁹ /L)	157.57±52.26, 155.00	144.86±46.07, 143.00	2.25	0.026	1.00 (1.00, 1.01)	0.012
ALT (U/L)	56.00 (38.00, 101.28)	56.00 (35.00, 101.28)	1.16	0.265		
AST (U/L)	41.00 (28.00, 70.00)	41.00 (30.09, 69.26)	1.11	0.239		
ALP (U/L)	87.15 (71.05, 109.22)	89.32 (71.28, 114.91)	-0.11	0.914		
GGT (U/L)	46.00 (28.50, 80.00)	42.78 (24.91, 83.81)	-0.16	0.870		
ALB (g/L)	42.46±4.91, 43.00	41.68±4.81, 42.00	1.41	0.161		0.943
TBil (μmol/L)	14.70 (11.40, 20.80)	15.90 (11.45, 20.30)	1.27	0.177		0.217
DBil (μmol/L)	4.70 (3.21, 7.50)	4.70 (3.40, 7.65)	1.71	0.065		0.077
Cr (μmol/L)	66.97±14.13, 66.00	65.81±12.93, 65.40	0.75	0.457		
TCHO (mmol/L)	4.42±0.93, 4.31	4.23±0.74, 4.20	1.85	0.060		0.688
TG (mmol/L)	1.19±0.64, 1.01	1.08±0.50, 1.02	1.59	0.113		0.798
AFP (ng/mL)	4.53 (2.94, 12.98)	5.00 (3.10, 16.45)	-0.08	0.940		
INR	1.10±0.11, 1.08	1.11±0.15, 1.10	-1.43	0.154	0.10 (0.01, 0.87)	0.037
HBV DNA (log ₁₀ IU/mL)	5.62±1.90, 5.68	5.62±1.75, 5.83	-0.26	0.797		
HBsAg (log ₁₀ IU/mL)	3.32±0.69, 3.38	3.22±0.66, 3.31	1.32	0.189		0.092
HBeAg (+), n (%)	93/167 (55.7)	80/136 (58.8)	0.30	0.583		
qAnti-HBc (log ₁₀ IU/mL)	3.88±0.69, 3.90	3.81±0.83, 3.82	0.75	0.448		
LSM (kPa)	11.90 (8.50, 18.55)	13.45 (8.90, 19.90)	-0.64	0.520		
HAI			2.42	0.490		
≤4, n (%)	38 (22.5)	42 (30.0)				
5–6, n (%)	53 (31.4)	39 (27.9)				
7–9, n (%)	49 (29.0)	39 (27.9)				
≥10, n (%)	29 (17.2)	20 (14.3)				
F			30.67	0.000	2.49 (1.81, 3.42)	0.000
3–4	99 (58.6)	122 (87.1)				
5–6	70 (41.4)	18 (12.9)				

ALHX, An-Luo-Hua-Xian; ETV, Entecavir; F, liver histologic fibrosis score; HAI, liver histologic activity scores of inflammatory; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Cr, creatinine.

Ethical statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration. Informed consent was obtained from all patients for being included in the study.

Data sharing statement

Data supporting the findings of this study are available within the article and its supplementary materials.

References

- [1] GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392(10159):1736–1788. doi:10.1016/S0140-6736(18)32203-7, PMID:30496103.
- [2] Vittal A, Ghany MG. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. *Clin Liver Dis* 2019;23(3):417–432. doi:10.1016/j.cld.2019.04.008, PMID:31266617.
- [3] Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, *et al*. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018;67(4):1560–1599. doi:10.1002/hep.29800, PMID:29405329.
- [4] Cheng M, Feng X, Wang L, Yang Y, Ma L, Wang B. Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis. *Medicine (Baltimore)* 2020;99(27):e21032. doi:10.1097/md.00000000000021032, PMID:32629728.
- [5] Li H. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula. *J Ethnopharmacol* 2020;251:112442. doi:10.1016/j.jep.2019.112442, PMID:31891799.
- [6] National Medical Products Administration-data search. Available from: <https://www.nmpa.gov.cn/datasearch/search-result.html>.
- [7] Huang J, Huang H, Jiao Y, Ai G, Huang T, Li L, *et al*. Effect of anluohuaxian tablet combined with gamma-IFN on schistosoma liver fibrosis. *J Huazhong Univ Sci Technolog Med Sci* 2009;29(1):53–58. doi:10.1007/s11596-009-0111-7, PMID:19224163.
- [8] Miao L, Yang WN, Dong XQ, Zhang ZQ, Xie SB, Zhang DZ, *et al*. [Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection]. *Zhonghua Gan Zang Bing Za Zhi* 2019;27(7):521–526. doi:10.3760/cma.j.issn.1007-3418.2019.07.009, PMID:31357778.
- [9] Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, *et al*. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22(6):696–699. doi:10.1016/0168-8278(95)80226-6, PMID:7560864.
- [10] European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol* 2015;63(1):237–264. doi:10.1016/j.jhep.2015.04.006, PMID:25911335.
- [11] Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update. *Zhonghua Gan Zang Bing Za Zhi* 2019;27(3):182–191. doi:10.3760/cma.j.issn.1007-3418.2019.03.004, PMID:30929334.
- [12] Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, *et al*. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. *J Hepatol* 2016;64(4):773–780. doi:10.1016/j.jhep.2015.11.012, PMID:26626497.
- [13] Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, *et al*. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. *Lancet Gastroenterol Hepatol* 2019;4(7):538–544. doi:10.1016/S2468-1253(19)30087-1, PMID:30975477.
- [14] Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, *et al*. Non-invasive models for predicting histology in patients with chronic hepatitis B. *Liver Int* 2006;26(6):666–672. doi:10.1111/j.1478-3231.2006.01287.x, PMID:16842322.
- [15] Kong QF, Mei GT, Yang YX, Li Y, Shao YF, Miu XQ. Entecavir combined with Anluohuaxian pills in the treatment of 56 patients with hepatitis B cirrhosis: a 5-year analysis. *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases* 2020;30(06):506–508.
- [16] Lu W, Gao YH, Wang ZZ, Cai YS, Yang YQ, Miao YQ, *et al*. [Effects of Anluohuaxianwan on transforming growth factor-β1 and related signaling pathways in rats with carbon tetrachloride-induced liver fibrosis]. *Zhonghua Gan Zang Bing Za Zhi* 2017;25(4):257–262. doi:10.3760/cma.j.issn.1007-3418.2017.04.005, PMID:28494543.
- [17] Wang L, Lu W, Gao YH, Yan HJ, Pei F, Liu XE, *et al*. Anluohuaxianwan alleviates carbon tetrachloride-induced hepatic fibrosis in rats through upregulation of peroxisome proliferator-activated receptor-Gamma and downregulation of nuclear factor-Kappa B/IκBα signaling pathway. *World Journal of Traditional Chinese Medicine* 2019;5(2):95–103. doi:10.4103/wjtc.wjtc_16_19.
- [18] She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. *J Biol Chem* 2005;280(6):4959–4967. doi:10.1074/jbc.M410078200, PMID:15537655.
- [19] Rong G, Chen Y, Yu Z, Li Q, Bi J, Tan L, *et al*. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *J Infect Dis* 2022;225(6):1091–1099. doi:10.1093/infdis/jiaa266, PMID:32437567.
- [20] Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, *et al*. Effect of Fufang Biejia-Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. *Medicine (Baltimore)* 2019;98(17):e15297. doi:10.1097/md.00000000000015297, PMID:31027094.
- [21] Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, *et al*. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. *World J Gastroenterol* 2005;11(19):2892–2899. doi:10.3748/wjg.v11.i19.2892, PMID:15902724.
- [22] Gui HL, Zhao CQ, Wang Y, Gu HT, Wang WJ, Cai W, *et al*. Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis. *J Clin Transl Hepatol* 2020;8(3):277–284. doi:10.14218/jct.2020.00004, PMID:33083250.
- [23] Liu HL, Lv J, Zhao ZM, Xiong AM, Tan Y, Glenn JS, *et al*. Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. *Sci Rep* 2019;9(1):18719. doi:10.1038/s41598-019-54663-4, PMID:31822697.
- [24] Poisson J, Lemoine S, Boulanger C, Durand F, Moreau R, Valla D, *et al*. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. *J Hepatol* 2017;66(1):212–227. doi:10.1016/j.jhep.2016.07.009, PMID:27423426.
- [25] Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, *et al*. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2013;11(12):1636–1645.e1-3. doi:10.1016/j.cgh.2013.04.043, PMID:23669307.
- [26] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021, PMID:28427875.
- [27] McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, *et al*. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. *Gastroenterology* 2019;156(2):384–399. doi:10.1053/j.gastro.2018.07.058, PMID:30268787.